<?xml version="1.0" encoding="UTF-8"?>
<ref id="B42-pharmaceuticals-12-00101">
 <label>42.</label>
 <element-citation publication-type="gov">
  <person-group person-group-type="author">
   <collab>Tychan Pte Ltd.</collab>
  </person-group>
  <article-title>Safety and Tolerability of an Antibody Against Zika Virus (Tyzivumab) in ZIKV Infected Patients. ClinicalTrials.gov. NCT number: NCT03776695. 2018 Dec. NCT03776695</article-title>
  <comment>Available online: 
   <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03776695" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT03776695</ext-link>
  </comment>
  <date-in-citation content-type="access-date" iso-8601-date="2019-05-30">(accessed on 30 May 2019)</date-in-citation>
 </element-citation>
</ref>
